The genetically modified bacteria spark an RNAi response in the parasite that leads to self-destruction—and perhaps a path to combatting colony collapse disorder.

From the effects of political upheaval on research to claims of gene-edited babies, the year has been a tumultuous one for the scientific community.

Alnylam’s patisiran interferes with the production of a mutated protein present in people with hereditary transthyretin amyloidosis.

If approved, patisiran will be the first RNAi therapeutic on the market. 

Researchers engineer bacterial CRISPR-Cas13 to knock down RNA in mammalian cells.

Two freely available databases include data on hundreds of human cancer cell lines. 

A new study adds to the evidence that mammalian cells can use small interfering RNAs to defend against viruses, but questions remain about physiological importance.

This month, the EPA registered four products that include RNA interference technology intended to control corn rootworms. 

Our guide to all known forms of RNA, from cis-NAT to vault RNA and everything in between.